D. Smart
Neuroscience Research
SmithKline Beecham Pharmaceuticals
New Frontiers Science Park
Third Avenue
UK
Name/email consistency: medium
- SB-334867-A: the first selective orexin-1 receptor antagonist. Smart, D., Sabido-David, C., Brough, S.J., Jewitt, F., Johns, A., Porter, R.A., Jerman, J.C. Br. J. Pharmacol. (2001)
- Characterisation using FLIPR of human vanilloid VR1 receptor pharmacology. Smart, D., Jerman, J.C., Gunthorpe, M.J., Brough, S.J., Ranson, J., Cairns, W., Hayes, P.D., Randall, A.D., Davis, J.B. Eur. J. Pharmacol. (2001)
- The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Smart, D., Gunthorpe, M.J., Jerman, J.C., Nasir, S., Gray, J., Muir, A.I., Chambers, J.K., Randall, A.D., Davis, J.B. Br. J. Pharmacol. (2000)
- The hypocretins are weak agonists at recombinant human orexin-1 and orexin-2 receptors. Smart, D., Jerman, J.C., Brough, S.J., Neville, W.A., Jewitt, F., Porter, R.A. Br. J. Pharmacol. (2000)
- Characterisation using microphysiometry of CRF receptor pharmacology. Smart, D., Coppell, A., Rossant, C., Hall, M., McKnight, A.T. Eur. J. Pharmacol. (1999)
- Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR. Smart, D., Jerman, J.C., Brough, S.J., Rushton, S.L., Murdock, P.R., Jewitt, F., Elshourbagy, N.A., Ellis, C.E., Middlemiss, D.N., Brown, F. Br. J. Pharmacol. (1999)